WO2024107037A1 - Composition antioxydante et de blanchiment comprenant des cellules mortes d'enterococcus faecalis traitées thermiquement - Google Patents

Composition antioxydante et de blanchiment comprenant des cellules mortes d'enterococcus faecalis traitées thermiquement Download PDF

Info

Publication number
WO2024107037A1
WO2024107037A1 PCT/KR2023/095079 KR2023095079W WO2024107037A1 WO 2024107037 A1 WO2024107037 A1 WO 2024107037A1 KR 2023095079 W KR2023095079 W KR 2023095079W WO 2024107037 A1 WO2024107037 A1 WO 2024107037A1
Authority
WO
WIPO (PCT)
Prior art keywords
dead cells
enterococcus faecalis
present
antioxidant
heat
Prior art date
Application number
PCT/KR2023/095079
Other languages
English (en)
Korean (ko)
Inventor
한권일
이유라
진용훈
김준형
변지민
허철성
박현준
이채원
이대우
문은정
Original Assignee
베름주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020220184146A external-priority patent/KR20240073718A/ko
Application filed by 베름주식회사 filed Critical 베름주식회사
Publication of WO2024107037A1 publication Critical patent/WO2024107037A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Definitions

  • the present invention relates to a composition for sulfation and whitening containing Enterococcus faecalis as an active ingredient, and more specifically, to a composition for sulfation and whitening containing Enterococcus faecalis or dead cells thereof as an active ingredient. It relates to composition.
  • Human skin is composed of the epidermis, dermis, and connective tissue, including the stratum corneum.
  • the stratum corneum is composed of a layer of dead cells formed through the differentiation process of keratinocytes, the basal cells of the epidermis. It plays a role in protecting the human body from the effects of the external environment.
  • oxidative stress When oxidative stress is applied to skin cells by reactive oxygen species generated from biochemical reactions that continuously occur to supply the energy needed in the human body, cell components such as lipids, proteins, It causes oxidative damage to carbohydrates and DNA and changes enzyme activity, causing various diseases such as skin cancer and accelerating aging.
  • UV rays the largest cause of external aging is photoaging caused by ultraviolet rays, which causes acute and chronic skin injuries such as skin cancer through continuous exposure to UV rays.
  • the biosynthesis and decomposition of collagen which is one of the important components of the dermal layer matrix of the skin, is key to suppressing skin aging.
  • the reactive oxygen species promote the expression of MMPs (matrix metalloproteinases) in skin fibroblasts, and collagen production by ultraviolet rays It causes skin aging by promoting the synthesis of chemicals.
  • elastin fibers form cross-links with collagen and are an important skin component in wrinkle formation, which is involved in skin elasticity. Deficiency and aggregation of elastin fibers and a significant increase in the activity of elastase, an elastin decomposing enzyme, have been found to be one of the factors causing skin wrinkles.
  • Elastase is the only enzyme that can decompose elastin, and its inhibition is known to fundamentally reduce the improvement of skin wrinkles. Meanwhile, a person's skin color is determined by the concentration and distribution of melanin inside the skin, and in addition to genetic factors, it is also affected by environmental or physiological conditions such as solar ultraviolet rays, fatigue, and stress.
  • Melanin is synthesized in melanocytes in the epidermal layer of the skin.
  • melanosomes an organelle within melanocytes, an enzyme called tyrosinase acts on tyrosine, a type of amino acid, to produce DOPA, It is converted to dopaquinone and then produced through a non-enzymatic oxidation reaction. If this synthesis of melanin occurs excessively within the skin, it darkens the skin tone and causes spots, freckles, etc.
  • microorganisms of the Enterococcus genus exist widely in nature and use carbohydrates aerobically.
  • bacteria such as Enterococcus genus microorganisms prevent damage caused by pathogenic microorganisms through in vivo antagonistic effects or secreted antibacterial substances.
  • Enterococcus faecalis EF2001 was identified through screening the intestinal flora of a 2-year-old girl. This Enterococcus faecalis EF-2001 was killed by heat treatment and the bacterial cell components were recovered to form dead cells of Enterococcus faecalis EF-2001.
  • Enterococcus faecalis EF-2001 suppresses the activity of Candida albican, the cause of efflorescence, showing symptom improvement and prevention effects (Ishijima et al., Med. Mycol. J, 2014 ), the efficacy of which beneficial bacteria proliferate faster and harmful bacteria are suppressed in mice administered antibiotics compared to the intestinal control group has been disclosed (Simohashi et al., Medicine and biology, 2002).
  • the purpose of the present invention is to provide a composition for sulfation and whitening containing heat-treated dead cells of Enterococcus faecalis EF-2001 in order to solve the above problems.
  • the present invention provides a composition for sulfation and whitening containing heat-treated dead cells of Enterococcus faecalis EF-2001.
  • composition for sulfation and whitening containing heat-treated dead cells of Enterococcus faecalis EF-2001 of the present invention has excellent DPPH free radical scavenging activity, has an antioxidant effect, and has a tyrosinase inhibitory effect, thereby providing a whitening effect.
  • composition for sulfation and whitening containing heat-treated dead cells of Enterococcus faecalis EF-2001 of the present invention has no cytotoxicity or skin side effects and can be safely used in cosmetic, pharmaceutical and food compositions.
  • Figure 1 is a diagram showing the DPPH radical scavenging rate of heat-treated dead cells of Enterococcus faecalis EF-2001 according to an embodiment of the present invention.
  • Figure 2 is a diagram showing the tyrosinase inhibitory activity of heat-treated dead cells of Enterococcus faecalis EF-2001 according to an embodiment of the present invention.
  • Figure 3 is a diagram showing the confirmation of tyrosinase expression in melanoma cell line of Enterococcus faecalis EF-2001 heat-treated dead cells according to an embodiment of the present invention.
  • Figure 4 is a diagram showing the effect of inhibiting melanin production in heat-treated dead cells of Enterococcus faecalis EF-2001 according to an embodiment of the present invention.
  • Figure 5 is a diagram showing the DOPA oxidation activity inhibition ability of Enterococcus faecalis EF-2001 heat-treated dead cells according to an embodiment of the present invention.
  • Figure 6 is a diagram showing the ability to inhibit L-DOPA oxidation activity of heat-treated dead cells of Enterococcus faecalis EF-2001 according to an embodiment of the present invention.
  • the present invention provides an antioxidant and whitening composition containing Enterococcus faecalis or one or more dead cells thereof as an active ingredient.
  • the Enterococcus faecalis is preferably registered as Enterococcus faecalis EF-2001 (domestic accession number: KCTC SD1560), but is not limited thereto.
  • the Enterococcus faecalis or its dead cells may be either commercially available or prepared by a known dead cell production method, and are non-toxic and harmless to the human body.
  • the dead cells can be prepared by heat-treating the corresponding live cells or treating them with formalin or other disinfectants, and the dead cells can be used even if they are substantially dead.
  • the dead cells are cultured by a conventional method, washed, centrifuged, and washed. After repeating the washing and dehydration as necessary, the dead cells are suspended in distilled water, physiological saline, etc., and the suspension is, for example, Examples include a dead cell suspension or its dried product obtained by heating at 80 to 115°C for 30 minutes to 3 seconds, or a dead cell suspension or its dried product obtained by irradiating the dead cell suspension with gamma rays or neutron rays.
  • the means for drying the dead cell suspension is not particularly limited as long as it is a known drying means, and examples include spray drying and freeze drying.
  • enzyme treatment, surfactant treatment, and trituration/pulverization treatment may be performed before or after sterilization treatment by heating or the like, or before or after drying treatment, and products obtained by these treatments are also included in the dead cells of the present invention. do.
  • the dead cells can be prepared by the following method, but are not limited to this:
  • the main culture is carried out at pH 4.0 to 9.0 and a temperature of 15 to 45°C, more preferably at pH 5.0 to 8.0 and a temperature of 20 to 40°C;
  • step 2) Heat treating the Enterococcus faecalis cultured in step 1) at a temperature of 60 to 140°C for 1 to 40 minutes, more preferably at a temperature of 70 to 130°C for 5 to 30 minutes, followed by drying and powdering.
  • composition for sulfation and whitening containing heat-treated dead cells of Enterococcus faecalis EF-2001 of the present invention exhibits antioxidant and whitening effects and, as a natural substance, has little cytotoxicity.
  • a cosmetic composition for sulfation and whitening containing heat-treated dead cells of Enterococcus faecalis EF-2001 is provided.
  • the cosmetic composition according to one embodiment of the present invention includes, in addition to the heat-treated dead cells of Enterococcus faecalis EF-2001 as an active ingredient, ingredients commonly added to cosmetic compositions, such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances. Conventional auxiliaries such as, and carriers may be additionally added.
  • the cosmetic composition of the present invention can be prepared in any formulation commonly prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing agents. , oil, powder foundation, emulsion foundation, wax foundation, spray, etc., but is not limited thereto. More specifically, it can be manufactured in the form of nutritional cream, astringent lotion, softening lotion, lotion, essence, nutritional gel, or massage cream.
  • the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, gum tracant, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide are used as carrier ingredients. It can be.
  • the formulation of the present invention is a powder or spray
  • toss talc
  • silica aluminum hydroxide
  • calcium silicate or polyamide powder
  • toss talc
  • silica aluminum hydroxide
  • calcium silicate or polyamide powder
  • toss talc
  • silica aluminum hydroxide
  • calcium silicate or polyamide powder
  • chlorofluorohydrocarbon and propane may be used as carrier ingredients.
  • May contain propellants such as butane or dimethyl ether.
  • a solvent, solubilizer or emulsifier is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 , 3-butyl glycol oil, fatty esters of glycerol, fatty acid esters of polyethylene glycol or sorbitan.
  • the carrier ingredients include water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester, and miso.
  • a liquid diluent such as ethanol or propylene glycol
  • a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester
  • miso Crystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracant gum can be used.
  • the carrier ingredients include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, and fatty acid amide ether.
  • Sulfates, alkylamidobetaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives, or ethoxylated glycerol fatty acid esters may be used.
  • the pharmaceutical composition according to one embodiment of the present invention includes a pharmaceutically acceptable carrier in addition to the heat-treated dead cells of Enterococcus faecalis EF-2001.
  • Pharmaceutically acceptable carriers included in the pharmaceutical composition of the present invention are those commonly used in preparation, and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginate, gelatin, Contains calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. It is not limited.
  • the pharmaceutical composition of the present invention may further include lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc.
  • lubricants wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc.
  • suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).
  • composition of the present invention can be administered orally or parenterally, and is preferably applied by topical application rather than parenteral administration.
  • the appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, administration method, patient's age, weight, gender, pathological condition, food, administration time, administration route, excretion rate, and reaction sensitivity. may be prescribed.
  • the dosage of the pharmaceutical composition of the present invention is within the range of 0.001-100 mg/kg for adults.
  • the above dosage does not limit the scope of the present invention.
  • the pharmaceutical composition of the present invention is prepared in unit dosage form or in multi-dose form by formulating it using pharmaceutically acceptable carriers and/or excipients according to a method that can be easily performed by those skilled in the art. It can be manufactured by placing it in a container. At this time, the formulation may be in the form of a solution, suspension, syrup or emulsion in an oil or aqueous medium, or may be in the form of an exyl, powder, powder, granule, tablet or capsule, and may additionally contain a dispersant or stabilizer.
  • the food composition according to one embodiment of the present invention contains not only Enterococcus faecalis EF-2001 heat-treated dead cells as an active ingredient, but also ingredients commonly added during food production, such as proteins, carbohydrates, fats, and nutrients. , seasonings and flavoring agents may be additionally included.
  • Such carbohydrates include monosaccharides such as glucose, fructose, etc.; Disaccharides such as maltose, sucrose, oligosaccharides, etc.; and polysaccharides, such as common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • sweetening agents natural flavoring agents (thaumatin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used.
  • the food composition of the present invention when manufactured as a drink, in addition to the heat-treated dead cells of Enterococcus faecalis EF-2001 of the present invention, citric acid, high fructose corn syrup, sugar, glucose, acetic acid, malic acid, fruit juice, cephalic acid extract, jujube extract, and licorice. Extracts, etc. may be additionally included.
  • the antioxidant and whitening composition containing heat-treated dead cells of Enterococcus faecalis EF-2001 of the present invention is a natural substance that is harmless to the human body and has almost no toxicity or side effects, so it can be used safely even for long-term use. It can be safely applied to cosmetic, pharmaceutical and food compositions as described above.
  • Enterococcus faecalis EF-2001 heat-treated dead cells were prepared as follows.
  • the medium is pre-cultured by aerobic or anaerobic culture in a medium used for general lactic acid bacteria culture, and then cultured for 1 to 3 days while maintaining pH 5.0 to 8.0 and 20 to 40°C to obtain a dry weight (DW) of 7.5 ⁇ Main culture was performed to reach a cell count of 10 12 cells/g or more.
  • the cells were killed by heat treatment at 70 to 130°C for 5 to 30 minutes. After heat treatment, the cells were separated and recovered using a continuous centrifuge, then spray-dried and powdered.
  • Example 1 Measurement of DPPH free radical scavenging activity of a composition containing heat-treated dead cells of Enterococcus faecalis EF-2001 (DPPH free radical scavenging assay)
  • the 1,1-diphenyl-2-picrylhydrazyl (DPPH) free radical scavenging activity for measuring the antioxidant activity of the composition prepared in Preparation Example 1 was confirmed by the electron donating activity to DPPH.
  • DPPH forms an irreversibly stable molecule by receiving electrons or hydrogen from antioxidant substances, so the antioxidant activity can be measured from the electron donating ability.
  • free radicals are generated. This is erased, and at this time, DPPH's unique blue-black color has the characteristic of becoming lighter, and this color difference is colorimetrically quantified to measure the electron donating ability (Jeon et al., J. Kor. Soc. Food sic. Nutr. 38(1) : 1-8, 2009).
  • the heat-treated dead cells of Enterococcus faecalis EF-2001 (EF-2001) of the present invention were diluted to final concentrations (13.3, 6.67, 1.33 mg/mL) and performed as follows.
  • test substance was prepared for Enterococcus faecalis EF-2001 heat-treated dead cells (EF-2001) of the present invention so that the administration concentration in Table 1 was the final concentration.
  • test substance 100 ⁇ L was dispensed by concentration into a 96 well plate, 100 ⁇ L of DPPH reagent was added to a and b, and 100 ⁇ L of ethanol was added to a and b and reacted in the dark for 30 minutes.
  • the absorbance was measured at a wavelength of 517 nm, and the DPPH free radical scavenging ability was calculated according to the following equation.
  • the heat-treated dead cells of Enterococcus faecalis EF-2001 (EF-2001) of the present invention contained 17.1 ⁇ 2.8 and 12.6 ⁇ 2.9% at final concentrations of 13.3 and 6.67 mg/mL, respectively.
  • DPPH showed free radical scavenging activity.
  • tyrosinase a protein important in melanin synthesis, inhibits melanin production.
  • the heat-treated dead cells of Enterococcus faecalis EF-2001 (EF-2001) of the present invention were incubated at different concentrations (10, 30, 100, 300 and 1000 ⁇ g/ml) using the microplate method. ) was processed and confirmed.
  • B16F10 cells mouse-derived melanoma cells
  • DMEM Dulbeco's modified essential medium
  • ⁇ -MSH which promotes melanogenesis
  • melanogenesis was induced in B16F10 cells, mouse-derived melanoma cells, by adding ⁇ -MSH.
  • EF-2001 was used at different concentrations (10, 30, 100, 300, 1000). ⁇ g/ml).
  • A is the reaction absorbance of the sample solution
  • B is the reaction absorbance of the blank sample solution.
  • the heat-treated dead cells of Faecalis EF-2001 (EF-2001) of the present invention have an inhibitory ability of 13.03%, showing superior DOPA oxidation compared to the control and comparison group KCTC 3163 ( Lactobacillus gasseri KCTC 3163, LAB). It was confirmed that there was an activity inhibition effect.
  • Faecalis EF-2001 heat-treated dead cells were dissolved in PBS and diluted to three final concentrations (13.3, 6.67, 1.33 mg/mL) and performed as follows.
  • the reagent was prepared by dissolving tyrosinase in PBS at 1.5 U/ ⁇ L.
  • L-DOPA was dissolved in PBS and prepared at 3mM.
  • Enterococcus faecalis EF-2001 heat-treated dead cells were prepared with PBS so that the final concentration in Table 1 was obtained, and then mixed with 850 ⁇ L of PBS, 50 ⁇ L of sample, and 50 ⁇ L of 1.5 U/ ⁇ L tyrosinase solution. I put it in. 50 ⁇ L of 3mM L-DOPA solution was added to the solution and reacted at 37°C for 30 minutes. After dispensing 100 ⁇ L into a 96 well plate, the absorbance was measured at 475 nm.
  • the L-DOPA oxidation inhibition ability (%) was calculated as follows.
  • EF-2001 of the present invention was used and treated with PBS to a final concentration of 13.3, 6.67, and 1.33 mg/mL.
  • the L-DOPA oxidation inhibition effect was confirmed to be 24.7 ⁇ 7.0 and 12.5 ⁇ 5.8% at concentrations of 13.3 and 6.67 mg/mL, respectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition antioxydante et de blanchiment comprenant des cellules mortes d'Enterococcus faecalis traitées thermiquement (EF-2001). Dans un mode de réalisation, la composition antioxydante et de blanchiment comprenant des cellules mortes d'Enterococcus faecalis traitées thermiquement (EF-2001) selon l'invention ne présente pas de cytotoxicité ni d'effets secondaires cutanés, et peut donc être utilisée en toute sécurité dans des produits cosmétiques et des compositions alimentaires.
PCT/KR2023/095079 2022-11-18 2023-11-16 Composition antioxydante et de blanchiment comprenant des cellules mortes d'enterococcus faecalis traitées thermiquement WO2024107037A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2022-0155531 2022-11-18
KR20220155531 2022-11-18
KR1020220184146A KR20240073718A (ko) 2022-11-18 2022-12-26 엔테로코커스 페칼리스 열처리 사균체를 포함하는 항산화 및 미백용 조성물
KR10-2022-0184146 2022-12-26

Publications (1)

Publication Number Publication Date
WO2024107037A1 true WO2024107037A1 (fr) 2024-05-23

Family

ID=91085155

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/095079 WO2024107037A1 (fr) 2022-11-18 2023-11-16 Composition antioxydante et de blanchiment comprenant des cellules mortes d'enterococcus faecalis traitées thermiquement

Country Status (1)

Country Link
WO (1) WO2024107037A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080092090A (ko) * 2007-04-11 2008-10-15 주식회사 두산 유산균 파쇄액을 함유하는 피부 미백용 조성물
KR20170123122A (ko) * 2016-04-28 2017-11-07 연세대학교 원주산학협력단 엔테로코커스 패칼리스, 이의 배양액 또는 이의 사균체를 유효성분으로 함유하는 근육감퇴, 약화 및 근위축 예방, 개선 또는 치료용 약학 조성물, 식품 조성물 및 식품첨가제
KR20190041864A (ko) * 2017-10-13 2019-04-23 연세대학교 원주산학협력단 엔테로코커스 패칼리스를 유효성분으로 함유하는 염증성 질환 예방 또는 치료용 조성물
KR102249398B1 (ko) * 2020-10-20 2021-05-07 강영기 열처리 유산균 사균체를 포함하는 보이차 추출물 및 그 제조방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080092090A (ko) * 2007-04-11 2008-10-15 주식회사 두산 유산균 파쇄액을 함유하는 피부 미백용 조성물
KR20170123122A (ko) * 2016-04-28 2017-11-07 연세대학교 원주산학협력단 엔테로코커스 패칼리스, 이의 배양액 또는 이의 사균체를 유효성분으로 함유하는 근육감퇴, 약화 및 근위축 예방, 개선 또는 치료용 약학 조성물, 식품 조성물 및 식품첨가제
KR20190041864A (ko) * 2017-10-13 2019-04-23 연세대학교 원주산학협력단 엔테로코커스 패칼리스를 유효성분으로 함유하는 염증성 질환 예방 또는 치료용 조성물
KR102249398B1 (ko) * 2020-10-20 2021-05-07 강영기 열처리 유산균 사균체를 포함하는 보이차 추출물 및 그 제조방법

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GU YEUN-HWA, CHOI HYUNJU; YAMASHITA TAKENORI; KANG KI-MUN; IWASA MASAHIRO; LEE MOON-JO; LEE KYOUNG H.; KIM CHEORL-HO: "Pharmaceutical Production of Anti-tumor and Immune-potentiating Enterococcus faecalis-2001 β-glucans: Enhanced Activity of Macrophage and Lymphocytes in Tumor-implanted Mice", CURRENT PHARMACEUTICAL BIOTECHNOLOGY, BENTHAM SCIENCE PUBLISHERS,, NL, vol. 18, no. 8, 10 November 2017 (2017-11-10), NL , XP093170561, ISSN: 1389-2010, DOI: 10.2174/1389201018666171002130428 *
HYO-JIN KANG,TAE-WOON KIM,JIN-WOO JHOO, GUR-YOO KIM: "Antioxidant Effects of Fermented Milk Added with Enterococcus faecalis EF-2001 Heat-Killed Probiotics", ANNALS OF ANIMAL RESOURCE SCIENCES, LNSTITUE OF ANIMAL LIFE SCIENCE, KR, vol. 31, no. 2, 1 January 2020 (2020-01-01), KR, pages 72 - 81, XP009555163, ISSN: 1225-2964, DOI: 10.12718/AARS.2020.31.2.72 *

Similar Documents

Publication Publication Date Title
WO2020060060A1 (fr) Composition cosmétique comprenant un extrait de racine adventive de centella asiatica en tant que principe actif pour le blanchiment de la peau et la réduction des rides
WO2020218846A1 (fr) Composition de blanchiment de la peau comprenant un exosome de lait
WO2022145663A1 (fr) Composition cosmétique comprenant une masse de bactéries lactiques lactobacillus plantarum mortes ou une culture de bactéries lactiques destinée à prévenir ou à atténuer le vieillissement de la peau
WO2021162415A1 (fr) Composition cosmétique pour l'amélioration de la peau comprenant, en tant que principes actifs, des polysaccharides, un extrait de levure et un produit de fermentation de souche ayant des caractéristiques de probiotiques
WO2019103329A1 (fr) Composition antioxydante contenant un extrait de ver de farine fermenté à titre de principe actif
WO2020246766A1 (fr) Composition pour prévenir ou atténuer le vieillissement cutané, contenant un extrait de rhodiola sachalinensis fermenté à l'aide de bovista plumbea
WO2022080839A1 (fr) Composition antioxydante, anti-inflammatoire et de blanchiment comprenant des bactéries d'acide lactique dérivées de la peau
WO2020218888A1 (fr) Composition cosmétique pour le blanchiment de la peau contenant de nouvelles lactobacillus rhamnosus lm1011 en tant que principe actif
WO2018117725A1 (fr) Composition pour prévenir la chute des cheveux et favoriser la pousse des cheveux, comprenant des produits animaux marins fermentés
WO2017200288A1 (fr) Composition pour le blanchiment de la peau, la prévention du vieillissement de la peau ou l'amélioration des rides de la peau, comprenant un extrait médicinal oriental naturel en tant que substance active
WO2012173382A2 (fr) Composition à usage externe pour l'épiderme, contenant du tanshinone ii a en tant que principe actif
WO2024107037A1 (fr) Composition antioxydante et de blanchiment comprenant des cellules mortes d'enterococcus faecalis traitées thermiquement
WO2013115456A1 (fr) Aliment, substance cosmétique, ou composition pharmaceutique contenant un extrait supercritique de gingembre et un extrait de résidu de persil japonais fermenté
WO2022169246A1 (fr) Composition de matière cosmétique
WO2021215882A1 (fr) Composition pour prévenir la chute des cheveux ou favoriser la pousse des cheveux comprenant un extrait de péricarpe de camélia en tant que principe actif
WO2009107984A2 (fr) Composition contre le vieillissement de la peau contenant des extraits de pousses de plantes
WO2020111540A1 (fr) Composition pharmaceutique pour la prévention ou le traitement du vieillissement ou de maladies associées au vieillissement, comprenant un complexe d'anthocyanine-polysaccharide en tant que principe actif
KR101273027B1 (ko) 캄페롤을 유효성분으로 함유하는 피지 분비 억제용 및항비만용 조성물
KR102152407B1 (ko) 스피루리나에서 유래한 파이코시아노블린 및 이의 유도체를 유효성분으로 포함하는 화장료 조성물
KR20240073718A (ko) 엔테로코커스 페칼리스 열처리 사균체를 포함하는 항산화 및 미백용 조성물
WO2021075929A1 (fr) Composition comprenant un extrait de feuille d'artemisia princeps, pour le soulagement de lésions cutanées
WO2019225891A1 (fr) Composition contre le vieillissement de la peau contenant de l'irilin b
WO2023191471A1 (fr) Composition pour le blanchiment de la peau et procédé de blanchiment de la peau l'utilisant
WO2022114784A1 (fr) Composition comprenant un produit de fermentation d'une huile de cactus et son utilisation pour améliorer l'état de la peau
WO2022045638A1 (fr) Composition destinée à améliorer l'état de la peau contenant, en tant que principe actif, un extrait de nid de pétrel-tempête fermenté à l'aide d'une nouvelle souche du genre lactobacillus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23892099

Country of ref document: EP

Kind code of ref document: A1